Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004874 · ClinicalTrials.gov registry record · Phase 3
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT00004874 is a Phase 3 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 31 participants.
The verdict
NCT00004874, a Phase 3 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- RADIATION tositumomab and iodine I 131 tositumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 1998-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004874
The ClinicalTrials.gov registry entry for NCT00004874 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tositumomab and iodine I 131 tositumomab is the first listed.
NCT00004874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004874 about?
NCT00004874 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Ho...
What is the current status of trial NCT00004874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 1998-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00004874?
The interventions under investigation include: tositumomab and iodine I 131 tositumomab (RADIATION).
Who is sponsoring clinical trial NCT00004874?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.